Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-0.78% $2.53
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 115.30 mill |
EPS: | 0.130 |
P/E: | 19.46 |
Earnings Date: | Mar 29, 2024 |
SharesOutstanding: | 45.57 mill |
Avg Daily Volume: | 0.0845 mill |
RATING 2024-03-27 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Buy | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | n/a | n/a | ||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 19.46 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.41x |
Company: PE 19.46 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.43 - 2.63 ( +/- 4.11%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2017-09-15 | Gaenzle Christopher L | Sell | 4 245 | Class A Common Stock |
2017-09-18 | Gaenzle Christopher L | Sell | 4 682 | Class A Common Stock |
2017-09-18 | Rush Gregory S | Sell | 9 703 | Class A Common Stock |
2017-09-01 | Rush Gregory S | Buy | 71 005 | Class A Common Stock |
2017-09-01 | Rush Gregory S | Sell | 19 300 | Class A Common Stock |
INSIDER POWER |
---|
0.00 |
Last 95 transactions |
Buy: 444 688 | Sell: 598 851 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.53 (-0.78% ) |
Volume | 0.0868 mill |
Avg. Vol. | 0.0845 mill |
% of Avg. Vol | 102.75 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.